MX2023005313A - Anticuerpos fcrn y metodos de uso de estos. - Google Patents
Anticuerpos fcrn y metodos de uso de estos.Info
- Publication number
- MX2023005313A MX2023005313A MX2023005313A MX2023005313A MX2023005313A MX 2023005313 A MX2023005313 A MX 2023005313A MX 2023005313 A MX2023005313 A MX 2023005313A MX 2023005313 A MX2023005313 A MX 2023005313A MX 2023005313 A MX2023005313 A MX 2023005313A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- methods
- fcrn
- antibodies
- fcrn antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110884P | 2020-11-06 | 2020-11-06 | |
| US202163137972P | 2021-01-15 | 2021-01-15 | |
| US202163173126P | 2021-04-09 | 2021-04-09 | |
| US202163173919P | 2021-04-12 | 2021-04-12 | |
| US202163174423P | 2021-04-13 | 2021-04-13 | |
| US202163175440P | 2021-04-15 | 2021-04-15 | |
| US202163203075P | 2021-07-07 | 2021-07-07 | |
| US202163203077P | 2021-07-07 | 2021-07-07 | |
| US202163219155P | 2021-07-07 | 2021-07-07 | |
| PCT/US2021/058188 WO2022098955A1 (en) | 2020-11-06 | 2021-11-05 | Fcrn antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005313A true MX2023005313A (es) | 2023-07-11 |
Family
ID=81455198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005313A MX2023005313A (es) | 2020-11-06 | 2021-11-05 | Anticuerpos fcrn y metodos de uso de estos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220144946A1 (https=) |
| EP (1) | EP4240417A4 (https=) |
| JP (1) | JP2023548858A (https=) |
| KR (1) | KR20230117575A (https=) |
| AU (1) | AU2021376364A1 (https=) |
| CA (1) | CA3200972A1 (https=) |
| IL (1) | IL302516A (https=) |
| JO (1) | JOP20230098A1 (https=) |
| MX (1) | MX2023005313A (https=) |
| PH (1) | PH12023551241A1 (https=) |
| TW (1) | TW202233236A (https=) |
| WO (1) | WO2022098955A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12240875B2 (en) | 2017-12-08 | 2025-03-04 | argenx BV | Use of FCRN antagonists for treatment of generalized myasthenia gravis |
| KR102904658B1 (ko) | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| CA3101462A1 (en) | 2018-06-08 | 2019-12-12 | Argenx Bvba | Compositions and methods for treating immune thrombocytopenia |
| KR102921210B1 (ko) | 2018-07-20 | 2026-01-30 | 모멘타 파머슈티컬스 인코포레이티드 | Fcrn 항체 조성물 |
| BR112022013554A2 (pt) | 2020-01-08 | 2022-09-06 | argenx BV | Métodos para tratar distúrbios do pênfigo |
| CA3258000A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE |
| EP4615481A1 (en) * | 2022-11-07 | 2025-09-17 | argenx BV | Methods for treating lupus nephritis using fcrn antagonists |
| WO2024163894A1 (en) * | 2023-02-04 | 2024-08-08 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating hemolytic disease of the fetus and newborn |
| TW202527982A (zh) * | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025163617A1 (en) * | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2025186787A1 (en) * | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250052465A (ko) * | 2015-01-30 | 2025-04-18 | 모멘타 파머슈티컬스 인코포레이티드 | ＦｃＲｎ 항체 및 이의 사용 방법 |
| CA3038894A1 (en) * | 2016-09-28 | 2018-04-05 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| US12240875B2 (en) * | 2017-12-08 | 2025-03-04 | argenx BV | Use of FCRN antagonists for treatment of generalized myasthenia gravis |
| KR102904658B1 (ko) * | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| MX2021000790A (es) * | 2018-07-20 | 2021-07-21 | Momenta Pharmaceuticals Inc | Composiciones de anticuerpos del receptor neonatal para fc y metodos de uso de las mismas. |
| MA53903A (fr) * | 2018-10-16 | 2021-08-25 | UCB Biopharma SRL | Méthode de traitement de la myasthénie grave |
| EP4007605A4 (en) * | 2019-08-01 | 2023-08-16 | Momenta Pharmaceuticals, Inc. | ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF |
-
2021
- 2021-11-05 IL IL302516A patent/IL302516A/en unknown
- 2021-11-05 EP EP21890118.9A patent/EP4240417A4/en active Pending
- 2021-11-05 CA CA3200972A patent/CA3200972A1/en active Pending
- 2021-11-05 WO PCT/US2021/058188 patent/WO2022098955A1/en not_active Ceased
- 2021-11-05 TW TW110141386A patent/TW202233236A/zh unknown
- 2021-11-05 PH PH1/2023/551241A patent/PH12023551241A1/en unknown
- 2021-11-05 KR KR1020237018942A patent/KR20230117575A/ko active Pending
- 2021-11-05 JP JP2023526977A patent/JP2023548858A/ja active Pending
- 2021-11-05 US US17/519,811 patent/US20220144946A1/en active Pending
- 2021-11-05 MX MX2023005313A patent/MX2023005313A/es unknown
- 2021-11-05 AU AU2021376364A patent/AU2021376364A1/en active Pending
-
2023
- 2023-05-04 JO JOJO/P/2023/0098A patent/JOP20230098A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230117575A (ko) | 2023-08-08 |
| CA3200972A1 (en) | 2022-05-12 |
| TW202233236A (zh) | 2022-09-01 |
| IL302516A (en) | 2023-07-01 |
| AU2021376364A9 (en) | 2024-09-12 |
| EP4240417A1 (en) | 2023-09-13 |
| JOP20230098A1 (ar) | 2023-05-04 |
| PH12023551241A1 (en) | 2023-11-20 |
| AU2021376364A1 (en) | 2023-06-22 |
| WO2022098955A1 (en) | 2022-05-12 |
| US20220144946A1 (en) | 2022-05-12 |
| EP4240417A4 (en) | 2024-10-02 |
| WO2022098955A9 (en) | 2022-06-09 |
| JP2023548858A (ja) | 2023-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12023551241A1 (en) | Fcrn antibodies and methods of use thereof | |
| AU2018386193A8 (en) | FcRn antibodies and methods of use thereof | |
| MX2022001380A (es) | Anticuerpos de fcrn y metodos de uso de los mismos. | |
| EP4286011A3 (en) | Fcrn antibodies and methods of use thereof | |
| EP4282487A3 (en) | Fcrn antibodies and methods of use thereof | |
| PH12020552018A1 (en) | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies | |
| Hu et al. | Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE+ B cells | |
| PH12021550802A1 (en) | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof | |
| JOP20210071A1 (ar) | أجسام مضادة مثبّتة trem2 | |
| CO2020001029A2 (es) | Molécula de polipéptido con especificidad dual mejorada | |
| WO2020016662A3 (en) | Antibodies specific to trophoblast antigen 2 (trop2) | |
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| EA201692192A1 (ru) | СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ | |
| SA522431508B1 (ar) | hK2 مستقبل المستضدات الخيمري لـ (CAR) المضاد | |
| EA201990171A1 (ru) | Биспецифичное антитело против egfr и против cd3 и его применения | |
| JOP20210169B1 (ar) | أجسام مضادة أحادية النسيلة ضد منطقة سلسلة بيتا من trbv9 بشري | |
| EA201290589A1 (ru) | Cd127-связывающие белки | |
| JOP20200161A1 (ar) | أجسام مضادة أحادية النسيلة وطرق استخدامها | |
| MX380702B (es) | Proteinas de union al antigeno del receptor de oncostatina m. | |
| JOP20210168B1 (ar) | أجسام مضادة أحادية النسيلة ترتبط نوعيًا مع trbv9 بشري | |
| Thibult et al. | CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells | |
| MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
| NZ750451A (en) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 | |
| MY204368A (en) | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof | |
| AR112228A1 (es) | Molécula de polipéptido con especificidad dual mejorada |